TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and efficacy of TCRαβ+/CD19+ depleted
allogeneic hematopoietic stem cell transplant (HSCT) for malignant and non-malignant
disorders in children and adolescent/young adult patients using the CliniMACS® immunomagnetic
selection device (Miltenyi Biotec).